Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer

  • Authors:
    • Nan-Yung Hsu
    • Ya-Wen Cheng
    • I-Ping Chan
    • Heng-Chien Ho
    • Chih-Yi Chen
    • Chung-Ping Hsu
    • Meng-Hung Lin
    • Ming-Chih Chou
  • View Affiliations

  • Published online on: January 1, 2009     https://doi.org/10.3892/or_00000192
  • Pages: 81-87
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The clinical significance of HPV-16/18 E6 oncoprotein expression in non-small cell lung cancer (NSCLC) is not fully known. A study was undertaken to investigate the association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I NSCLC. We analyzed a series of 217 patients with stage I NSCLC for the presence of HPV-16/18 E6 oncoprotein by immunohistochemistry. HPV-16 E6 oncoprotein was expressed in 49 (22.6%) patients and HPV-18 E6 oncoprotein was expressed in 31 (14.3%) patients. Statistical analysis revealed that the prevalence of expression of HPV-16 and HPV-18 E6 oncoproteins was significantly high in female patients, nonsmokers and patients with adenocarcinoma. The adjusted odds ratio for expression of HPV-16 E6 oncoprotein in female patients was 2.275 [95% confidence interval (CI), 0.999-5.179] and that in patients with adenocarcinoma was 2.320 (95% CI, 1.029-5.232). These ratios were significantly higher than those in male patients and patients with squamous cell carcinoma. Interestingly, we found that the 17 patients who expressed HPV-16 and HPV-18 E6 oncoprotein had a higher 5-year cumulate survival rate (72.2%) than the 154 patients who did not express both oncoproteins (48.3%); the difference was significant (p=0.055). Expression of HPV-16/18 E6 oncoprotein in stage I NSCLC may play an important role in female adenocarcinoma patients and survival benefits in patients who expressed HPV-16 and HPV-18 E6 oncoprotein.

Related Articles

Journal Cover

January 2009
Volume 21 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hsu N, Cheng Y, Chan I, Ho H, Chen C, Hsu C, Lin M and Chou M: Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. Oncol Rep 21: 81-87, 2009
APA
Hsu, N., Cheng, Y., Chan, I., Ho, H., Chen, C., Hsu, C. ... Chou, M. (2009). Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. Oncology Reports, 21, 81-87. https://doi.org/10.3892/or_00000192
MLA
Hsu, N., Cheng, Y., Chan, I., Ho, H., Chen, C., Hsu, C., Lin, M., Chou, M."Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer". Oncology Reports 21.1 (2009): 81-87.
Chicago
Hsu, N., Cheng, Y., Chan, I., Ho, H., Chen, C., Hsu, C., Lin, M., Chou, M."Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer". Oncology Reports 21, no. 1 (2009): 81-87. https://doi.org/10.3892/or_00000192